Depodrag® Equine

Injectable suspension.

Steroidal anti-inflammatory.

Horses.

Each 1 mL of suspension contains:
Triamcinolone Acetonide………… 6 mg
Excipients q.s………………………….1 mL

Anti-inflammatory depot for allergic, dermatological disorders and arthritis.

Intramuscular, subcutaneous, intrasynovial and intra-articular.

12 – 30 mg intramuscularly or subcutaneously. Intra-articular or intrasynovial administration should be carried out in a single injection of 6 – 30 mg, which can be repeated after 3 to 4 days if necessary.

• Intramuscular or subcutaneous route: 2 to 5 mL in a single dose.
• Intra-articular or intrasynovial route: 1 to 5 mL in a single dose. Repeat if necessary under Veterinary Medical recommendation.

It is not advisable to repeat the treatment more than 3 consecutive times.

Prolonged use of Depodrag® can cause suppressive effects on the hypothalamic-pituitary-adrenal axis leading to adrenal atrophy (adrenal insufficiency). It can also cause bone resorption or inhibition of bone growth and repair, inhibition of collagen synthesis, decreased growth rate, delayed healing, diarrhea, gastrointestinal irritation, gastrointestinal ulceration, hematopoietic changes, sodium and calcium retention. fluid and recrudescence of latent infections.
The most common side effects are polyuria, polydipsia, polyphagia, lethargy, weakness and bilateral alopecia. Less common are weight loss, anorexia and diarrhea.

• In bacterial infections the use should be associated with antibacterials.
• Corticosteroids can precipitate labor during the final stages of pregnancy.
• Shake before use.
• Keep out of reach of children and pets.

• Do not use in viral infectious processes and generalized fungal infections.
• Do not use in musculoskeletal disorders where immobility is required.
• Do not use in animals with tuberculosis, chronic nephritis or Cushing’s syndrome, except for emergency therapy.
• Do not use in case of bone metaplasia and osteoporosis.
• Do not use in the treatment of laminitis.
• Do not use in patients with diabetes mellitus, kidney or heart failure.
• Do not use in patients with hypersensitivity to the active ingredient.
• Do not use in animals with gastrointestinal or corneal ulcer.
• Do not use in pregnant or lactating females.

• Do not use in pregnant and lactating females.
• Glucocorticoids are probably necessary for normal fetal development. They may be required for adequate surfactant production and development of myelin, retina, pancreas, and breast.
• Excessive doses early in gestation may lead to teratogenic effects. In horses, the administration of exogenous steroids can induce parturition when used in the final stages of pregnancy. It is recommended not to use high doses in pregnant animals.
• Glucocorticoids not bound to plasma proteins enter milk. High doses or prolonged administration in mothers can potentially inhibit the growth of newborns.

• Amphotericin B or kaliuretic diuretics (Furosemide, Thiacides) can cause hypokalemia when administered concomitantly with glucocorticoids. When these drugs are used simultaneously with digitalis glycosides, the potential for toxicity may increase if hypokalemia occurs. Diligent monitoring of potassium and digitalis levels is recommended.
• Glucocorticoids can reduce blood levels of salicylates.
• Insulin requirements may increase in patients receiving glucocorticoids.
• Phenytoin, Phenobarbital, Rifampicin can increase the metabolism of glucocorticoids.
• Concomitant administration of glucocorticoids and cyclosporine may increase blood levels of each, with mutual inhibition of hepatic metabolism. The clinical significance of this interaction is uncertain. Glucocorticoids may also inhibit the hepatic metabolism of Cyclophosphamide. Dosage adjustments may be required.
• Mitotane can alter steroid metabolism; Larger doses than usual may be necessary to treat Mitotane-induced adrenal insufficiency.
• Patients treated with corticosteroids at immunosuppressive doses should not receive live attenuated virus vaccines because viral replication may be enhanced. A diminished immune response may occur after administration of a vaccine, toxoid, or bacterin, in patients receiving glucocorticoids.
• The administration of ulcerogenic drugs (e.g., non-steroidal anti-inflammatory drugs) with glucocorticoids may increase the risk of gastrointestinal ulceration.
• The effects of Hydrocortisone, and possibly other glucocorticoids, may be potentiated by concomitant administration with estrogens.
• In patients with myasthenia gravis, concomitant administration of glucocorticoids and anticholinesterases (e.g., Pyridostigmine, Neostigmine, etc.) may induce pronounced muscle weakness. If possible, discontinue anticholinesterase medication at least 24 hours before glucocorticoid administration.

Do not use in horses intended for human consumption.

The product is irritating in case of contact with the eyes. It can be dangerous in the case of accidental ingestion and in case of contact with the skin.
Pregnant women should not handle the product.

Discard unused product remains in their original packaging. Dispose of waste from this product with caution with household waste.
Uruguay: Discard the product container at the nearest collection center

Discard unused product remains in their original packaging. Dispose of waste from this product with caution with household waste.

Uruguay: Discard the product container at the nearest collection center

Sale under Veterinary Medical prescription.

VETERINARY USE
SHAKE BEFORE USE

Ampoule bottle with 20 mL and case containing 3 ampoule bottles with 5 mL each.

Chile: Reg. SAG N° 529
Bolivia: Reg. SENASAG PUV-F-N° 005515/13
Rep. Dominicana: Reg. N° 5607
Uruguay: Reg. MGAP N° A-4493
Perú: Reg. SENASA F.06.42.I.0240

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.